Chemomab Drops After Board Changes and CEO Stock Purchase
Chemomab Therapeutics’ shares fell 6.5% to $1.74 on Nasdaq Tuesday after a regulatory filing showed board changes, with Gwen Melincoff joining and two directors resigning. CEO Adi Mor George bought nearly $20,250 in shares last week. Cash stood at $8 million on March 31, enough to fund operations into early 2027. The company is advancing nebokitug for primary sclerosing cholangitis amid rising competition.